Ipatasertib Market Global Report 2026 Market Report Infographic Image

Published : March 2026

Pages :

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Ipatasertib Market Report 2026

Name: Ipatasertib Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Global Outlook – By Indication (Prostate Cancer, Breast Cancer, Other Cancers), By Dosage Form (Tablets, Capsules, Other Dosages), By Route Of Administration (Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, Strategies, and Forecast to 2035

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Purchase This Report Download Sample PDF

Item added to cart!

Ipatasertib Market Overview

• Ipatasertib market size has reached to $0.86 billion in 2025

• Expected to grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 13.1%

• Growth Driver: Increasing Prevalence Of Cancer Fueling The Growth Of The Market Due To Rising Cancer Incidences And Need For Targeted Therapies

• North America was the largest region in 2025.

What Is Covered Under Ipatasertib Market?

Ipatasertib is an oral, small-molecule inhibitor that selectively targets protein kinase B (AKT), a key protein in the phosphoinositide 3-kinase (PI3K) or protein kinase B (AKT) signaling pathway that is often overactive in cancer cells. It works by inhibiting protein kinase B (AKT) and disrupting cancer cell growth, survival, and proliferation, helping to slow cancer progression and enhance the effectiveness of other therapies.

The main indications of ipatasertib are prostate cancer, breast cancer, and others. Prostate cancer is a disease that develops in the prostate, a small gland in men responsible for producing seminal fluid. It is available in various dosage forms, including tablets, capsules, and others, and is administered through oral or intravenous routes. Ipatasertib is distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

Ipatasertib Market Global Report 2026 Market Report bar graph

What Is The Ipatasertib Market Size and Share 2026?

The ipatasertib market size has grown rapidly in recent years. It will grow from $0.86 billion in 2025 to $0.98 billion in 2026 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to advancements in pi3k/akt pathway research, increasing prevalence of advanced-stage cancers, growth of targeted oncology drug pipelines, expansion of clinical trials for small-molecule inhibitors, rising adoption of precision oncology approaches.

What Is The Ipatasertib Market Growth Forecast?

The ipatasertib market size is expected to see rapid growth in the next few years. It will grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to increasing regulatory approvals for targeted cancer drugs, rising demand for personalized cancer therapies, expansion of combination therapy strategies, growing investments in oncology R&D, increasing focus on resistant cancer treatment options. Major trends in the forecast period include increasing focus on akt pathway inhibition therapies, rising use of combination cancer treatment regimens, growing emphasis on biomarker-driven oncology drugs, expansion of targeted small-molecule pipelines, enhanced clinical evaluation of precision oncology agents.

Book your 30 minutes free consultation with our research experts

Global Ipatasertib Market Segmentation

1) By Indication: Prostate Cancer, Breast Cancer, Other Cancers

2) By Dosage Form: Tablets, Capsules, Other Dosages

3) By Route Of Administration: Oral, Intravenous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Prostate Cancer: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Non-Metastatic Prostate Cancer

2) By Breast Cancer: Triple-Negative Breast Cancer (TNBC), Hormone Receptor-Positive Or Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

3) By Other Cancers: Ovarian Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Lung Cancer

What Are The Drivers Of The Ipatasertib Market?

The increasing prevalence of cancer is expected to propel the growth of the ipatasertib market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The increasing prevalence of cancer is due to lifestyle choices such as poor diet, smoking, physical inactivity, and excessive alcohol consumption. Ipatasertib enhances cancer treatment strategies by targeting the PI3K/AKT signaling pathway, making it effective in slowing tumor growth and proliferation. It reduces cancer cell survival and resistance to therapy, improving treatment outcomes and patient prognosis. For instance, in April 2024, according to the American Cancer Society (ACS) and the International Agency for Research on Cancer (IARC), there were 20 million new cancer cases in 2022, up from previous estimates, with projections to reach 35 million by 2050, representing a 77% increase. Therefore, the increasing prevalence of cancer is driving the growth of the ipatasertib industry.

The rising preference for personalized medicine is expected to propel the growth of the ipatasertib market going forward. Personalized medicine refers to a medical approach that tailors treatment and prevention strategies to an individual’s unique genetic makeup, lifestyle, and environment. The increasing adoption of personalized medicine is primarily due to advancements in genomics, which enable precise identification of genetic variations and tailored treatments for individuals. Ipatasertib enhances personalized medicine by targeting the PI3K/AKT signaling pathway, making cancer treatment more tailored to individual patient tumor profiles. It improves therapeutic effectiveness by addressing specific genetic and molecular characteristics, reducing treatment resistance, and optimizing patient outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the rising preference for personalized medicine is driving the growth of the ipatasertib industry.

The rising healthcare expenditure is expected to propel the growth of the ipatasertib market going forward. Healthcare expenditure refers to the total amount of money spent on medical services, treatments, facilities, research, and public health initiatives to maintain or improve health outcomes. The increasing demand for healthcare expenditure is due to the rising prevalence of chronic diseases, which require long-term and costly treatments. Rising healthcare expenditure enhances Ipatasertib development by providing increased funding and resources for research and clinical trials, making it easier to advance innovative cancer therapies. It accelerates drug development timelines and supports broader access to targeted treatments, improving patient outcomes and treatment efficiency. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms in 2023, an increase of 0.9% growth compared to 2022. Therefore, the rising healthcare expenditure is driving the growth of the ipatasertib industry.

Key Players In The Global Ipatasertib Market

Major companies operating in the ipatasertib market are Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., BGI Genomics Co. Ltd., Invitae Corporation, Guardant Health Inc., GeneDx LLC, Ancestry Inc., Oxford Nanopore Technologies plc, Genomic Health Inc., 23andMe Holding Co., Color Health Inc., Helix OpCo LLC, Personalis Inc., Dante Genomics, Gene By Gene Ltd., Veritas Genetics Inc., Futura Genetics, Nebula Genomics Inc., Pathway Genomics Corporation

Need data on a specific region in this market?

Request Regional Data

Regional Insights

North America was the largest region in the ipatasertib market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Ipatasertib Market?

The ipatasertib market consists of sales of capivasertib (AZD5363), perifosine, afuresertib (GSK2110183), MK-2206, and taselisib (GDC-0032). Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ipatasertib Market Report 2026?

The ipatasertib market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ipatasertib industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Ipatasertib Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$0.98 billion
Revenue Forecast In 2035	$1.6 billion
Growth Rate	CAGR of 13.4% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Indication, Dosage Form, Route Of Administration, Distribution Channel
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., BGI Genomics Co. Ltd., Invitae Corporation, Guardant Health Inc., GeneDx LLC, Ancestry Inc., Oxford Nanopore Technologies plc, Genomic Health Inc., 23andMe Holding Co., Color Health Inc.
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Ipatasertib Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Ipatasertib Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Ipatasertib Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Ipatasertib Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics And Precision Medicine

4.1.2 Artificial Intelligence And Autonomous Intelligence

4.1.3 Industry 4.0 And Intelligent Manufacturing

4.1.4 Digitalization, Cloud, Big Data And Cybersecurity

4.1.5 Sustainability, Climate Tech And Circular Economy

4.2. Major Trends

4.2.1 Increasing Focus On Akt Pathway Inhibition Therapies

4.2.2 Rising Use Of Combination Cancer Treatment Regimens

4.2.3 Growing Emphasis On Biomarker-Driven Oncology Drugs

4.2.4 Expansion Of Targeted Small-Molecule Pipelines

4.2.5 Enhanced Clinical Evaluation Of Precision Oncology Agents

5. Ipatasertib Market Analysis Of End Use Industries

5.1 Oncology Hospitals

5.2 Specialty Cancer Clinics

5.3 Research Laboratories

5.4 Pharmaceutical Companies

5.5 Clinical Trial Centers

6. Ipatasertib Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Ipatasertib Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Ipatasertib PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Ipatasertib Market Size, Comparisons And Growth Rate Analysis

7.3. Global Ipatasertib Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Ipatasertib Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Ipatasertib Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Ipatasertib Market Segmentation

9.1. Global Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Prostate Cancer, Breast Cancer, Other Cancers

9.2. Global Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Tablets, Capsules, Other Dosages

9.3. Global Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Oral, Intravenous

9.4. Global Ipatasertib Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

9.5. Global Ipatasertib Market, Sub-Segmentation Of Prostate Cancer, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Non-Metastatic Prostate Cancer

9.6. Global Ipatasertib Market, Sub-Segmentation Of Breast Cancer, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Triple-Negative Breast Cancer (TNBC), Hormone Receptor-Positive Or Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

9.7. Global Ipatasertib Market, Sub-Segmentation Of Other Cancers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Ovarian Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Lung Cancer

10. Ipatasertib Market Regional And Country Analysis

10.1. Global Ipatasertib Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Ipatasertib Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Ipatasertib Market

11.1. Asia-Pacific Ipatasertib Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Ipatasertib Market

12.1. China Ipatasertib Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Ipatasertib Market

13.1. India Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Ipatasertib Market

14.1. Japan Ipatasertib Market Overview

14.2. Japan Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Ipatasertib Market

15.1. Australia Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Ipatasertib Market

16.1. Indonesia Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Ipatasertib Market

17.1. South Korea Ipatasertib Market Overview

17.2. South Korea Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Ipatasertib Market

18.1. Taiwan Ipatasertib Market Overview

18.2. Taiwan Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Ipatasertib Market

19.1. South East Asia Ipatasertib Market Overview

19.2. South East Asia Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Ipatasertib Market

20.1. Western Europe Ipatasertib Market Overview

20.2. Western Europe Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Ipatasertib Market

21.1. UK Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Ipatasertib Market

22.1. Germany Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Ipatasertib Market

23.1. France Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Ipatasertib Market

24.1. Italy Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Ipatasertib Market

25.1. Spain Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Ipatasertib Market

26.1. Eastern Europe Ipatasertib Market Overview

26.2. Eastern Europe Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Ipatasertib Market

27.1. Russia Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Ipatasertib Market

28.1. North America Ipatasertib Market Overview

28.2. North America Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Ipatasertib Market

29.1. USA Ipatasertib Market Overview

29.2. USA Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Ipatasertib Market

30.1. Canada Ipatasertib Market Overview

30.2. Canada Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Ipatasertib Market

31.1. South America Ipatasertib Market Overview

31.2. South America Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Ipatasertib Market

32.1. Brazil Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Ipatasertib Market

33.1. Middle East Ipatasertib Market Overview

33.2. Middle East Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Ipatasertib Market

34.1. Africa Ipatasertib Market Overview

34.2. Africa Ipatasertib Market, Segmentation By Indication, Segmentation By Dosage Form, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Ipatasertib Market Regulatory and Investment Landscape

36. Ipatasertib Market Competitive Landscape And Company Profiles

36.1. Ipatasertib Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Ipatasertib Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Ipatasertib Market Company Profiles

36.3.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. BGI Genomics Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Invitae Corporation Overview, Products and Services, Strategy and Financial Analysis

37. Ipatasertib Market Other Major And Innovative Companies

Guardant Health Inc., GeneDx LLC, Ancestry Inc., Oxford Nanopore Technologies plc, Genomic Health Inc., 23andMe Holding Co., Color Health Inc., Helix OpCo LLC, Personalis Inc., Dante Genomics, Gene By Gene Ltd., Veritas Genetics Inc., Futura Genetics, Nebula Genomics Inc., Pathway Genomics Corporation

38. Global Ipatasertib Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Ipatasertib Market

40. Ipatasertib Market High Potential Countries, Segments and Strategies

40.1 Ipatasertib Market In 2030 - Countries Offering Most New Opportunities

40.2 Ipatasertib Market In 2030 - Segments Offering Most New Opportunities

40.3 Ipatasertib Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Ipatasertib Market, Overview Of Key Products - Product Examples

Table 2: Global Ipatasertib Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Ipatasertib Market, Supply Chain Analysis

Table 4: Global Ipatasertib Market, Major Raw Material Providers

Table 5: Global Ipatasertib Market, Major Resource Providers

Table 6: Global Ipatasertib Market, Major Manufacturers (Suppliers)

Table 7: Global Ipatasertib Market, Major Distributors And Channel Partners

Table 8: Global Ipatasertib Market, Key Technologies & Future Trends

Table 9: Global Ipatasertib Market, Major Trends

Table 10: Global Ipatasertib Market, Major End Users

Table 11: Global Ipatasertib Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Ipatasertib Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Ipatasertib Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Ipatasertib Market - TAM, US$ Billion, 2025

Table 15: Global Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Ipatasertib Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Ipatasertib Market, Sub-Segmentation Of Prostate Cancer, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global Ipatasertib Market, Sub-Segmentation Of Breast Cancer, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global Ipatasertib Market, Sub-Segmentation Of Other Cancers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Global Ipatasertib Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Global Ipatasertib Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Asia-Pacific, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: Asia-Pacific, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: Asia-Pacific, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: China, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: China, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: China, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: India, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: India, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: India, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: Japan, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: Japan, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: Japan, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Australia, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Australia, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Australia, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Indonesia, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Indonesia, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: Indonesia, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: South Korea, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: South Korea, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: South Korea, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: Taiwan, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: Taiwan, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: Taiwan, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: South East Asia, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: South East Asia, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: South East Asia, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: Western Europe, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: Western Europe, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: Western Europe, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: UK, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: UK, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: UK, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: Germany, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: Germany, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: Germany, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: France, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: France, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: France, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: Italy, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: Italy, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: Italy, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Spain, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Spain, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Spain, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Eastern Europe, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Eastern Europe, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Eastern Europe, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Russia, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: Russia, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: Russia, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: North America, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: North America, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: North America, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: USA, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: USA, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: USA, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: Canada, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: Canada, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: Canada, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: South America, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: South America, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: South America, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: Brazil, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: Brazil, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: Brazil, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Middle East, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Middle East, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Middle East, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Africa, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Africa, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 95: Africa, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 96: Global Ipatasertib Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 97: Global Ipatasertib Market - Company Scoring Matrix

Table 98: Thermo Fisher Scientific Inc. Financial Performance

Table 99: Illumina Inc. Financial Performance

Table 100: Myriad Genetics Inc. Financial Performance

Table 101: BGI Genomics Co. Ltd. Financial Performance

Table 102: Invitae Corporation Financial Performance

Table 103: Global Ipatasertib Market, Competitive Benchmarking (In USD Billions)

Table 104: Global Ipatasertib Market, Competitive Dashboard

Table 105: Global Ipatasertib Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 106: Global, Ipatasertib Market Size Gain ($ Billion), Segmentation By Indication, 2025 – 2030

Table 107: Global, Ipatasertib Market Size Gain ($ Billion), Segmentation By Dosage Form, 2025 – 2030

Table 108: Global, Ipatasertib Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030

List Of Figures

Figure 1: Global Ipatasertib Market, Overview Of Key Products - Product Examples

Figure 2: Global Ipatasertib Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Ipatasertib Market, Supply Chain Analysis

Figure 4: Global Ipatasertib Market, Major Raw Material Providers

Figure 5: Global Ipatasertib Market, Major Resource Providers

Figure 6: Global Ipatasertib Market, Major Manufacturers (Suppliers)

Figure 7: Global Ipatasertib Market, Major Distributors And Channel Partners

Figure 8: Global Ipatasertib Market, Key Technologies & Future Trends

Figure 9: Global Ipatasertib Market, Major Trends

Figure 10: Global Ipatasertib Market, Major End Users

Figure 11: Global Ipatasertib Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Ipatasertib Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Ipatasertib Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Ipatasertib Market - TAM, US$ Billion, 2025

Figure 15: Global Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Ipatasertib Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Ipatasertib Market, Sub-Segmentation Of Prostate Cancer, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global Ipatasertib Market, Sub-Segmentation Of Breast Cancer, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global Ipatasertib Market, Sub-Segmentation Of Other Cancers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Global Ipatasertib Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Global Ipatasertib Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Asia-Pacific, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: Asia-Pacific, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: Asia-Pacific, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: China, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: China, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: China, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: India, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: India, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: India, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: Japan, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: Japan, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: Japan, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Australia, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Australia, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Australia, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Indonesia, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Indonesia, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: Indonesia, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: South Korea, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: South Korea, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: South Korea, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: Taiwan, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: Taiwan, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: Taiwan, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: South East Asia, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: South East Asia, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: South East Asia, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: Western Europe, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: Western Europe, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: Western Europe, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: UK, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: UK, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: UK, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: Germany, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: Germany, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: Germany, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: France, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: France, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: France, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: Italy, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: Italy, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: Italy, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Spain, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Spain, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Spain, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Eastern Europe, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Eastern Europe, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Eastern Europe, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Russia, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: Russia, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: Russia, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: North America, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: North America, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: North America, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: USA, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: USA, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: USA, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: Canada, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: Canada, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: Canada, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: South America, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: South America, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: South America, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: Brazil, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: Brazil, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: Brazil, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Middle East, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Middle East, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Middle East, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Africa, Ipatasertib Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Africa, Ipatasertib Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 95: Africa, Ipatasertib Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 96: Global Ipatasertib Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 97: Global Ipatasertib Market - Company Scoring Matrix

Figure 98: Thermo Fisher Scientific Inc. Financial Performance

Figure 99: Illumina Inc. Financial Performance

Figure 100: Myriad Genetics Inc. Financial Performance

Figure 101: BGI Genomics Co. Ltd. Financial Performance

Figure 102: Invitae Corporation Financial Performance

Figure 103: Global Ipatasertib Market, Competitive Benchmarking (In USD Billions)

Figure 104: Global Ipatasertib Market, Competitive Dashboard

Figure 105: Global Ipatasertib Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 106: Global, Ipatasertib Market Size Gain ($ Billion), Segmentation By Indication, 2025 – 2030

Figure 107: Global, Ipatasertib Market Size Gain ($ Billion), Segmentation By Dosage Form, 2025 – 2030

Figure 108: Global, Ipatasertib Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

Naphthalene Sulfonate Market Report 2026 - Global Outlook – By Product Type (Naphthalene Sulfonic Acid, Sodium Naphthalene Sulfonate, Calcium Naphthalene Sulfonate, Other Product Types), By Form (Liquid, Powder), By Appl...

Darbepoetin Alfa (Aranesp) Market Report 2026 - Global Outlook – By Type (Epogen, Procrit, Aranesp, Other Types), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Application (Patients Wi...

Tofacitinib Market Report 2026 - Global Outlook – By Drug Class (Antirheumatic, Janus Kinase Inhibitor, Immunosuppressant), By Strength (5mg, 10mg, 11mg, 22mg), By Route Of Administration (Oral, Other Routes Of Administr...

Artichokes Market Report 2026 - Global Outlook – By Product Type (Baby Anzio, Big Heart, Green Globe, Siena, Mercury, Omaha, Fiesole, Chianti, Other Product Types), By Form (Fresh, Frozen, Canned), By Origin (Organic Art...

Osimertinib Drugs Market Report 2026 - Global Outlook – By Type (40 mg, 80 mg), By Distribution Channel (Hospital Pharmacy, Drug Store And Retail Pharmacy, Online Pharmacy), By Application (Locally Advanced Non-Small Cel...

Isopropyl Alcohol Market Report 2026 - Global Outlook – By Grade (70% IPA, 90% IPA), By Production Method (Indirect Hydration, Direct Hydration), By Application (Antiseptic And Astringent, Cleaning Agent, Solvent, Chemic...

Synthetic Emerald Market Report 2026 - Global Outlook – By Color Variant (Yellow-Green Emerald, Blue-Green Emerald, Pure Green Emerald), By Product (Hydrothermal Method, Flux-Growth Method, Skull Melting Method, Czochral...

Frequently Asked Questions

How big is the Ipatasertib Market?

The Ipatasertib market was valued at $0.86 billion in 2025, increased to $0.98 billion in 2026, and is projected to reach $1.6 billion by 2030.

What is the Ipatasertib market growth?

The global Ipatasertib market is expected to grow at a CAGR of 13.1% from 2026 to 2035 to reach $1.6 billion by 2035.

Who are the key players in Ipatasertib market?

Some Key Players in the Ipatasertib market Include, Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., BGI Genomics Co. Ltd., Invitae Corporation, Guardant Health Inc., GeneDx LLC, Ancestry Inc., Oxford Nanopore Technologies plc, Genomic Health Inc., 23andMe Holding Co., Color Health Inc., Helix OpCo LLC, Personalis Inc., Dante Genomics, Gene By Gene Ltd., Veritas Genetics Inc., Futura Genetics, Nebula Genomics Inc., Pathway Genomics Corporation .

What is the anticipated growth trend for the Ipatasertib market?

Major trend in this market includes: nan. For further insights on this market. request a sample here

Which region has the most growth potential in the Ipatasertib market?

North America was the largest region in the ipatasertib market in 2025. The regions covered in the ipatasertib market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.